▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s biotech firm Alteogen said on July 27 that it has developed a recombinant antibody that can facilitate conversion from intravenous type of protein therapeutics to a more con...
[THE INVESTOR] Korean cosmetics maker Amorepacific saw its second-quarter net profit jump 41.7 percent on-year on July 26, rebounding from last year’s slump sparked by the diplomatic tension between...
[THE INVESTOR] Samsung BioLogics , a contract drug maker, said on July 24 that it has obtained approval from the US Food and Drug Administration to manufacture a finished drug product. This is the...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis posted a whopping US$254 million sales in the European market in the first half of the year, data showed on July 25. According to the co...
[THE INVESTOR] Bukwang Pharmaceutical said on July 24 that its subsidiary Dyna Therapeutics plans to go public on the country’s secondary bourse KOSDAQ next year. Dyna Therapeutics, wholly owned b...
[THE INVESTOR] Korea has high potential to become a major part of the global biopharma business ecosystem with its openness for collaboration and swift clinical trial process, according to executive...
[THE INVESTOR] A patent licensing dispute between Reyon Pharmaceutical and ViroMed is intensifying as a gene therapy candidate developed by the latter is expected to become commercialized. Seou...
[THE INVESTOR] A civic activist group said on July 19 it has filed a complaint with the prosecution against the chief executive of Samsung BioLogics following Korea’s top financial regulator’s rulin...
[THE INVESTOR] Kolon Life Science said on July 18 that it has entered an agreement with a Chinese health care provider to export Invossa, an injectable cell gene therapy for osteoarthritis in a deal...
[THE INVESTOR] Johnson & Johnson subsidiary Janssen Pharmaceuticals will initiate new clinical trials for expanded use of HM12525A, a drug candidate originally developed by Hanmi Pharmaceutical , ...
[THE INVESTOR ] YD Global Life Science said on July 17 that it filed an application with the US Food and Drug Administration for phase 2a clinical trials of its diabetic retinopathy drug candidate Y...
[THE INVESTOR] Daewoong Pharmaceutical has hold its first ever non-deal roadshow to promote its botulinum toxin which is expected to be the first Botox biosimilar to hit the US market. The roadshow...
[THE INVESTOR] A long-standing controversy over Samsung BioLogics’ accounting practices has concluded for the time being as the country’s financial watchdog ruled that it clearly violated related ...
[THE INVESTOR] The Korean financial regulator said on July 12 it will refer Samsung BioLogics’ accounting “irregularity” to prosecutors after concluding that the contract drug manufacturer intenti...
[ THE INVESTOR] The Ministry of Food and Drug Safety said on July 12 it is testing a method to analyze cancer-causing residue in hypertension drugs’ key ingredient valsartan, manufactured by a Chin...
Samsung’s new smartphone with Infinity O display hints at upcoming Galaxy S10
Former MP Group chairman quits management
Hana Alternative Asset to acquire Booyoung’s building in Seoul
Samsung to hold biannual conference for global execs
Ananti shares soar on Jim Rogers’ appointment
E-mart acquires Good Food Holdings for US$275m
Toss lands US$80m investment to become Korea’s first fintech unicorn
Korean banks beef up their overseas biz
December 12, 2018
